moclobemide has been researched along with Phobic Disorders in 26 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Phobic Disorders: Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 9.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 5.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| "Moclobemide was superior for the reduction of the subjective general anxiety (BAI) during the first 3 months of treatment, but its influence on avoidant behavior (LSAS avoidance subscale) was less pronounced." | 2.72 | Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. ( Dockery, C; Horácek, J; Höschl, C; Houbová, P; Klaschka, J; Kosová, J; Pasková, B; Prasko, J; Praskova, H; Seifertová, D; Záleský, R, 2006) |
| "Moclobemide was significantly superior to placebo on 2 of 10 primary outcome measures." | 2.69 | Placebo-controlled trial of moclobemide in social phobia. ( Campeas, R; Fallon, B; Goetz, D; Liebowitz, MR; Marshall, R; Schneier, FR, 1998) |
| "Moclobemide was well tolerated." | 2.68 | The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. ( , 1997) |
| " Brofaromine dosage began at 50 mg/day and was titrated to a maximum of 150 mg/day, depending on treatment response." | 2.68 | Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. ( Greist, JH; Jefferson, JW; Katz, RJ; Katzelnick, DJ; Kobak, KA; Lott, M; Schaettle, SC, 1997) |
| "Moclobemide was well tolerated, insomnia being the only dose-related adverse event observed with the drug." | 2.68 | Moclobemide in social phobia: a controlled dose-response trial. ( Bell, J; Cain, JW; Curlik, SM; Davidson, A; Davidson, JR; Hedges, D; Kent, TA; Liebowitz, MR; Lydiard, RB; Mallinger, AG; Moroz, G; Noyes, R; Pollack, MH; Rapaport, M; Rasmussen, SA; Schweizer, E; Siegel, J; Uhlenhuth, EH, 1997) |
| "Moclobemide has been shown to have similar efficacy to tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and nonselective, irreversible MAO inhibitors." | 2.39 | Moclobemide. An update of its pharmacological properties and therapeutic use. ( Benfield, P; Fulton, B, 1996) |
| "Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression." | 2.39 | Moclobemide in the treatment of social phobia. ( Montgomery, SA; Nutt, D, 1996) |
| "Moclobemide has shown unequivocal antidepressant activity against serious depressive illness in 4 placebo-controlled double-blind trials." | 1.29 | Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. ( Gimbrett, R; Priest, RG; Roberts, M; Steinert, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 20 (76.92) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stein, DJ | 1 |
| Cameron, A | 1 |
| Amrein, R | 3 |
| Montgomery, SA | 4 |
| Atmaca, M | 1 |
| Kuloglu, M | 1 |
| Tezcan, E | 1 |
| Unal, A | 1 |
| Prasko, J | 1 |
| Dockery, C | 1 |
| Horácek, J | 1 |
| Houbová, P | 1 |
| Kosová, J | 1 |
| Klaschka, J | 1 |
| Pasková, B | 1 |
| Praskova, H | 1 |
| Seifertová, D | 1 |
| Záleský, R | 1 |
| Höschl, C | 1 |
| Mann, JJ | 1 |
| Aarons, SF | 1 |
| Frances, AJ | 1 |
| Brown, RD | 1 |
| Indran, SK | 1 |
| Priest, RG | 1 |
| Gimbrett, R | 1 |
| Roberts, M | 1 |
| Steinert, J | 1 |
| Marshall, RD | 1 |
| Schneier, FR | 5 |
| Fallon, BA | 2 |
| Feerick, J | 2 |
| Liebowitz, MR | 8 |
| Fulton, B | 1 |
| Benfield, P | 1 |
| Nutt, D | 1 |
| Versiani, M | 3 |
| Nardi, AE | 2 |
| Mundim, FD | 2 |
| Pinto, S | 1 |
| Saboya, E | 1 |
| Kovacs, R | 1 |
| Clarvit, SR | 1 |
| Lott, M | 1 |
| Greist, JH | 1 |
| Jefferson, JW | 1 |
| Kobak, KA | 1 |
| Katzelnick, DJ | 1 |
| Katz, RJ | 1 |
| Schaettle, SC | 1 |
| Noyes, R | 1 |
| Moroz, G | 1 |
| Davidson, JR | 1 |
| Davidson, A | 1 |
| Siegel, J | 1 |
| Bell, J | 1 |
| Cain, JW | 1 |
| Curlik, SM | 1 |
| Kent, TA | 1 |
| Lydiard, RB | 1 |
| Mallinger, AG | 1 |
| Pollack, MH | 1 |
| Rapaport, M | 1 |
| Rasmussen, SA | 1 |
| Hedges, D | 1 |
| Schweizer, E | 1 |
| Uhlenhuth, EH | 1 |
| Goetz, D | 1 |
| Campeas, R | 3 |
| Fallon, B | 2 |
| Marshall, R | 1 |
| Blanco, C | 1 |
| Duffett, R | 1 |
| Oosterbaan, DB | 1 |
| van Balkom, AJ | 1 |
| Spinhoven, P | 1 |
| de Meij, TG | 1 |
| van Dyck, R | 1 |
| Alves, AB | 1 |
| Hollander, E | 2 |
| Welkowitz, LA | 1 |
| Saoud, JB | 1 |
| Street, L | 1 |
| Gitow, A | 1 |
| Schneier, F | 1 |
| Welkowitz, L | 1 |
| Hatterer, J | 1 |
6 reviews available for moclobemide and Phobic Disorders
| Article | Year |
|---|---|
Medication therapy for social phobia.
Topics: Benzamides; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modali | 1994 |
Moclobemide. An update of its pharmacological properties and therapeutic use.
Topics: Age Factors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical | 1996 |
Moclobemide in the treatment of social phobia.
Topics: Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Moclobemide; Monoami | 1996 |
Social phobia: diagnosis, severity and implications for treatment.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Behavior Therapy; Benzamides; Benzodiazepines; Child | 1999 |
Treatment of social phobia with antidepressants.
Topics: Antidepressive Agents; Controlled Clinical Trials as Topic; Drug Approval; Humans; Moclobemide; Mono | 2001 |
Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
Topics: Antidepressive Agents; Benzamides; Borderline Personality Disorder; Bulimia; Combined Modality Thera | 1990 |
14 trials available for moclobemide and Phobic Disorders
| Article | Year |
|---|---|
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Drug Administr | 2002 |
Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.
Topics: Adolescent; Adult; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Moclobemide; | 2002 |
Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up.
Topics: Adolescent; Adult; Anxiety; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow- | 2006 |
Studies of selective and reversible monoamine oxidase inhibitors.
Topics: Animals; Benzamides; Blood Platelets; Brain; Clinical Trials as Topic; Depressive Disorder; Dopamine | 1984 |
Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dizziness; Female; Follow-Up Studies; | 1995 |
The long-term treatment of social phobia with moclobemide.
Topics: Adolescent; Adult; Benzamides; Female; Headache; Humans; Male; Middle Aged; Moclobemide; Monoamine O | 1996 |
The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.
Topics: Adult; Benzamides; Double-Blind Method; Female; Humans; Male; Moclobemide; Monoamine Oxidase Inhibit | 1997 |
Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Mocl | 1997 |
Moclobemide in social phobia: a controlled dose-response trial.
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Mocl | 1997 |
Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.
Topics: Adolescent; Adult; Antidepressive Agents; Benzamides; Female; Humans; Male; Middle Aged; Moclobemide | 1997 |
Placebo-controlled trial of moclobemide in social phobia.
Topics: Adolescent; Adult; Aged; Benzamides; Double-Blind Method; Female; Humans; Male; Middle Aged; Moclobe | 1998 |
Dimensional versus categorical response to moclobemide in social phobia.
Topics: Benzamides; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Personality Inventory; Phobic Disorde | 1998 |
The influence on treatment gain of comorbid avoidant personality disorder in patients with social phobia.
Topics: Adult; Age of Onset; Cognitive Behavioral Therapy; Comorbidity; Female; Follow-Up Studies; Humans; M | 2002 |
Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.
Topics: Adult; Benzamides; Comorbidity; Double-Blind Method; Female; Humans; Male; Middle Aged; Moclobemide; | 1992 |
6 other studies available for moclobemide and Phobic Disorders
| Article | Year |
|---|---|
Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
Topics: Alzheimer Disease; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 1995 |
Practical approaches to the treatment of social phobia.
Topics: Adrenergic beta-Antagonists; Behavior Therapy; Benzamides; Benzodiazepines; Bupropion; Clonazepam; C | 1994 |
Understanding social phobia. Proceedings of the IVth International Symposium on Moclobemide. Oslo, Norway, 15-16 September 1995.
Topics: Antidepressive Agents; Benzamides; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Phobic Disorde | 1996 |
The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Benzamides; Clonazepam; Culture; Diagnosis, Differential; Ethn | 1996 |
Moclobemide in social phobia.
Topics: Antidepressive Agents; Benzamides; Humans; Moclobemide; Phobic Disorders | 1998 |
Treatment of social phobia with drugs other than benzodiazepines.
Topics: Adolescent; Atenolol; Benzamides; Buspirone; Child; Clinical Trials as Topic; Female; Fluoxetine; Hu | 1991 |